Final Up to date on October 28, 2022 by GlobeNewsWire
SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) right this moment introduced the Firm will present a company replace and report monetary outcomes for the third quarter ended September 30, 2022, on Thursday, November 3, 2022.
The company replace and monetary outcomes might be offered by way of a press launch after market shut and might be accessible underneath Press Releases within the Buyers part of the Vir web site at www.vir.bio.
About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology firm centered on combining immunologic insights with cutting-edge applied sciences to deal with and stop critical infectious illnesses. Vir has assembled 4 expertise platforms which are designed to stimulate and improve the immune system by exploiting important observations of pure immune processes. Its present growth pipeline consists of product candidates focusing on COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts data that could be necessary to buyers on its web site.
